BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Approvals

  Adaptimmune’s Tecelra Becomes First FDA-Approved Engineered Cell Therapy for Solid Tumors

  Approved under the regulator’s accelerated pathway, Tecelra is also the first new synovial sarcoma therapy in more than a decade, according to Adaptimmune Therapeutics.

  August 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  RSV Vaccine Makers Hit Hard by New CDC Guidelines

  GSK, Moderna and Pfizer are all looking at potential respiratory syncytial virus vaccine sales slumps thanks to recently updated CDC guidelines regarding the use of RSV shots in seniors.

  August 2, 2024

   · 

  3 min read

   · 

  Greg Slabodkin
• 

  Earnings

  Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal

  As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.

  August 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  GSK Wins Broad Label Expansion for Jemperli in First-Line Endometrial Cancer

  In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in first-line endometrial cancer regardless of biomarker status.

  August 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pipeline

  Vertex Scraps Two Phase I AATD Candidates Following Disappointing Data

  Poor efficacy data for two early-stage candidates for the rare disease alpha-1 antitrypsin deficiency have convinced Vertex Pharmaceuticals to terminate their development.

  August 2, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

  August 2, 2024

   · 

  15 min read
• Business

  Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference

  August 2, 2024

   · 

  1 min read
• Press Releases

  Two Investigator-Initiated Responder Analysis Trials of Jaguar Health’s Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting

  August 2, 2024

   · 

  7 min read
• Press Releases

  Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

  August 2, 2024

   · 

  2 min read
• News

  EmVenio’s clinical research sites at Prime Healthcare hospitals now open in Dallas and Atlanta

  August 2, 2024

   · 

  4 min read